Demerger Spin Off Value Unlock
Expected: Q4 FY26MEDIUM confidence
What: Share Split: Board Approval
Titan Biotech Ltd: Why Is It Outperforming Nifty 500?
ActiveRS +129.6%Average4w StreakRe-Entry
In , Titan Biotech Ltd (Pesticides/Agrochemicals) is outperforming Nifty 500 with +129.6% relative strength. Fundamentals: Average. On a 4-week streak.
Titan Biotech Ltd Key Facts
- PE Ratio
- 70.3x
- Market Cap
- ₹1,913 Cr
- PAT Growth YoY
- +94%
- Revenue Growth YoY
- +48%
- OPM
- 19.2%
- RS vs Nifty 500
- +129.6%
PE: At PeakRiding Wave
What's Happening
📊PE near cycle highs — limited room for further expansion
📊Debt increased 200% YoY — leverage rising
💰Trading 82% above estimated fair value — significant premium
Earnings Acceleration Triggers
1. Demerger Spin Off Value Unlock
Q4 FY26MEDIUM
2. Operating Leverage Inflection
Q3 FY26HIGH
Key Risks
1. Receipt of legal notice invoking arbitration in a disputed matter
MEDIUM2. Rising commodity prices and monsoon uncertainty affecting the broader consumptio
LOWSector-Specific Signals
Operating Margin19.16%51.34%
Earnings Per Share₹10.3294.35%
Share in Profit from Associates₹66.04 LakhsNot Given
Standalone Revenue Growth55.6%55.6%
Key Numbers
PAT Growth YoY
+94%
Inflection Up
Revenue YoY
+48%
Inflection Up
Operating Margin
19.2%
+649 bps YoY
PE Ratio
70.3
Current Price
₹463
Dividend Yield
0.09%
Fundamental Score
48/100
Average
3Y PAT CAGR
0%
Market Cap
1.9K Cr
Valuation
Significantly Overvalued12-Week Performance
Weekly presence in the outperformers list. Green = beating Nifty 500 by 10%+ that week.
12 weeks agoThis week
Why Are Titan Biotech Ltd's Earnings Accelerating?
Based on Q3 FY26 (web) earnings • Updated Apr 19, 2026
Operating Leverage Inflection
Expected: Q3 FY26HIGH confidence
What: Operating Margin: 19.16%
Impact: 51.34% YoY increase
What Are the Key Risks for Titan Biotech Ltd?
Earnings deceleration risks from management commentary
Receipt of legal notice invoking arbitration in a disputed matter
MEDIUMTrigger: Receipt of legal notice invoking arbitration in a disputed matter.
Management view: Company is following regulatory disclosure norms.
Monitor: litigation
Rising commodity prices and monsoon uncertainty affecting the broader consumptio
LOWTrigger: Rising commodity prices and monsoon uncertainty affecting the broader consumption sector.
Management view: Not Given
Monitor: commodity
What Did Titan Biotech Ltd Report This Quarter?
Headline numbers from the latest earnings call
Revenue
₹56.51 Crore
YoY +47.62%QoQ +3.97%
Revenue growth was driven by strong market demand for biological products across standalone and consolidated operations.
EBITDA
₹10.83 Crore
YoY +123.3%Margin 19.16%
Operating margins expanded to 19.16% from 12.66% in the previous year's corresponding quarter due to operational efficiencies.
PAT
₹8.53 Crore
YoY +94.31%QoQ +9.92%
Consolidated PAT reached ₹8.53 crore, benefiting from a ₹66.04 lakhs share in profit from associate companies.
Other Highlights
• Standalone 9M FY26 revenue grew 29.7% YoY to ₹15,735.68 Lakhs.
• Basic EPS for Q3 FY26 jumped to ₹10.32 from ₹5.31 in Q3 FY25.
• Consolidated PBT grew 105.2% YoY to ₹1,052.86 Lakhs.
What Sector Metrics Matter for Titan Biotech Ltd?
Sub-sector-specific signals from the latest concall — each with management's stated reason for the change
Operating Margin
19.16%
YoY 51.34%QoQ 11.66%
Why: Effective cost management across various expense categories and operational efficiencies.
Earnings Per Share
₹10.32
YoY 94.35%QoQ 9.79%
Why: Driven by a 107% surge in standalone net profit and contributions from associate companies.
Share in Profit from Associates
₹66.04 Lakhs
YoY Not GivenQoQ Not Given
Why: Benefit from associate companies Peptech Biosciences Limited and Titan Media Limited.
Standalone Revenue Growth
55.6%
YoY 55.6%QoQ Not Given
Why: Strong market demand for biological products including peptone and culture media.
P/E Ratio (TTM)
12.78
YoY Not GivenQoQ Not Given
Why: Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 24.66 Cr.
Book Value
₹189
YoY Not GivenQoQ Not Given
Why: Reflects the accumulated equity and reserves as of the reporting date.
How Fast Is Titan Biotech Ltd Growing?
Revenue, profit and margin growth rates
| Metric | YoY | 3Y CAGR | Trend |
|---|---|---|---|
| Revenue | +48% | +8% | Inflection Up |
| PAT (Net Profit) | +94% | 0% | Inflection Up |
| OPM | 19.2% | +649 bps | Volatile |
The above analysis is parsed from publicly available earnings call transcripts. This is educational research only — not investment advice. Last updated Apr 19, 2026.
Other Top Pesticides/Agrochemicals Stocks Beating Nifty 500
Frequently Asked Questions: Titan Biotech Ltd
Based on publicly available financial data. This is educational research, not investment advice.
What were Titan Biotech Ltd's latest quarterly results?
Titan Biotech Ltd's latest quarterly results (Dec 2025) show
- PAT Growth YoY: +94.3% (turning around (inflection up))
- Revenue Growth YoY: +47.6%
- Operating Margin: 19.2% (volatile)
Is Titan Biotech Ltd's profit growing or declining?
Titan Biotech Ltd's profit is growing with an turning around (inflection up) trend.
- PAT Growth YoY: +94.3% (latest quarter)
- PAT Growth QoQ: +9.9% (sequential)
- 3-Year PAT CAGR: 0.0%
- Trend: Turning around (inflection up) — consistent growth pattern
What is Titan Biotech Ltd's revenue growth trend?
Titan Biotech Ltd's revenue growth trend is turning around (inflection up).
- Revenue Growth YoY: +47.6%
- Revenue Growth QoQ: +4.0% (sequential)
- 3-Year Revenue CAGR: +8.0%
How is Titan Biotech Ltd's operating margin trending?
Titan Biotech Ltd's operating margin is volatile.
- Current OPM: 19.2%
- OPM Change YoY: +6.5% basis points
- OPM Change QoQ: +2.0% basis points
What is Titan Biotech Ltd's 3-year profit and revenue CAGR?
Titan Biotech Ltd's long-term compounding rates
- 3-Year Profit CAGR: 0.0%
- 3-Year Revenue CAGR: +8.0%
Is Titan Biotech Ltd's growth accelerating or decelerating?
Titan Biotech Ltd's earnings growth is turning around (inflection up) with positive momentum on a sequential basis.
- YoY Acceleration: +78.5% bps
- Sequential Acceleration: -3.2% bps
What is Titan Biotech Ltd's trailing twelve month (TTM) performance?
Titan Biotech Ltd's trailing twelve month (TTM) performance
- TTM PAT: ₹27 Cr
- TTM PAT Growth: +20.9% YoY
- TTM Revenue: ₹193 Cr
- TTM Revenue Growth: +19.4% YoY
- TTM Operating Margin: 17.4%
Is Titan Biotech Ltd overvalued or undervalued?
Titan Biotech Ltd appears significantly overvalued based on our fair value analysis.
- Valuation Signal: Significantly Overvalued
- Current PE: 70.3x
- Price-to-Book: 11.5x
What is Titan Biotech Ltd's current PE ratio?
Titan Biotech Ltd's current PE ratio is 70.3x.
- Current PE: 70.3x
- Market Cap: 1.9K Cr
- Dividend Yield: 0.09%
How does Titan Biotech Ltd's valuation compare to its history?
Titan Biotech Ltd's current PE is 70.3x.
- Current PE: 70.3x
- Valuation Assessment: Significantly Overvalued
What is Titan Biotech Ltd's price-to-book ratio?
Titan Biotech Ltd's price-to-book ratio is 11.5x.
- Price-to-Book (P/B): 11.5x
- Book Value per Share: ₹40
- Current Price: ₹463
Is Titan Biotech Ltd a fundamentally strong company?
Titan Biotech Ltd is rated Average with a fundamental score of 47.51/100. This score is calculated from objective financial metrics
- Revenue Growth YoY: +47.6% (10% weight)
- PAT Growth YoY: +94.3% (10% weight)
- PAT Growth QoQ: +9.9% (10% weight)
- Margins stable (10% weight)
Is Titan Biotech Ltd debt free?
Titan Biotech Ltd has a debt-to-equity ratio of N/A.
- Total Debt: ₹3 Cr
What is Titan Biotech Ltd's return on equity (ROE) and ROCE?
Titan Biotech Ltd's return ratios over recent years
- FY2023: ROCE 27.0%
- FY2024: ROCE 25.0%
- FY2025: ROCE 17.0%
Is Titan Biotech Ltd's cash flow positive?
Titan Biotech Ltd's operating cash flow is positive (FY2025).
- Cash from Operations (CFO): ₹20 Cr
- Free Cash Flow (FCF): ₹10 Cr
- CFO/PAT Ratio: 91% (strong cash conversion)
What is Titan Biotech Ltd's dividend yield?
Titan Biotech Ltd's current dividend yield is 0.09%.
- Dividend Yield: 0.09%
- Current Price: ₹463
Who holds Titan Biotech Ltd shares — promoters, FII, DII?
Titan Biotech Ltd's shareholding pattern (Mar 2026)
- Promoters: 55.8%
- DII (Domestic): 0.0%
- Public: 44.2%
Is promoter holding increasing or decreasing in Titan Biotech Ltd?
Titan Biotech Ltd's promoter holding has remained stable recently.
- Current Promoter Holding: 55.8% (Mar 2026)
- Previous Quarter: 55.8% (Dec 2025)
- Change: 0.00% (stable)
How long has Titan Biotech Ltd been outperforming Nifty 500?
Titan Biotech Ltd has been outperforming Nifty 500 for 4 consecutive weeks, indicating building momentum.
Is Titan Biotech Ltd a new momentum entry or an established outperformer?
Titan Biotech Ltd is a re-entry — it briefly dropped off the outperformance list but has now returned. Re-entries can signal renewed strength.
What are the growth catalysts for Titan Biotech Ltd?
Titan Biotech Ltd has 2 key growth catalysts identified from recent earnings analysis
- Demerger Spin Off Value Unlock — A stock split typically improves liquidity and retail participation but does not change fundamental earnings power.
- Operating Leverage Inflection — Significant margin expansion indicates that revenue growth is falling to the bottom line efficiently.
What are the key risks in Titan Biotech Ltd?
Titan Biotech Ltd has 2 key risks worth monitoring
- [MEDIUM] Receipt of legal notice invoking arbitration in a disputed matter — Receipt of legal notice invoking arbitration in a disputed matter.
- [LOW] Rising commodity prices and monsoon uncertainty affecting the broader consumptio — Rising commodity prices and monsoon uncertainty affecting the broader consumption sector.
What is Titan Biotech Ltd's management guidance for growth?
Titan Biotech Ltd's management has provided the following forward guidance
- Revenue outlook: Not Given
- Margin outlook: Not Given
What sector-specific metrics matter most for Titan Biotech Ltd?
Titan Biotech Ltd's most important sub-sector-specific KPIs from the latest concall
- Operating Margin: 19.16% (YoY 51.34%) (QoQ 11.66%) — Effective cost management across various expense categories and operational efficiencies.
- Earnings Per Share: ₹10.32 (YoY 94.35%) (QoQ 9.79%) — Driven by a 107% surge in standalone net profit and contributions from associate companies.
- Share in Profit from Associates: ₹66.04 Lakhs (YoY Not Given) (QoQ Not Given) — Benefit from associate companies Peptech Biosciences Limited and Titan Media Limited.
- Standalone Revenue Growth: 55.6% (YoY 55.6%) (QoQ Not Given) — Strong market demand for biological products including peptone and culture media.
- P/E Ratio (TTM): 12.78 (YoY Not Given) (QoQ Not Given) — Calculated based on Trailing Twelve Months (TTM) Earnings of Rs 24.66 Cr.
- Book Value: ₹189 (YoY Not Given) (QoQ Not Given) — Reflects the accumulated equity and reserves as of the reporting date.
Is Titan Biotech Ltd worth studying for long term investment?
Based on quantitative research signals, here is why Titan Biotech Ltd may be worth studying
- Earnings growing at +94.3% YoY
- Cash flow is positive — CFO ₹20 Cr
What is the investment thesis for Titan Biotech Ltd?
Titan Biotech Ltd investment thesis summary:
Research Signals (Bull Case)
- Revenue growing at +47.6% YoY
- Growth catalyst: Demerger Spin Off Value Unlock
Risk Factors (Bear Case)
- Appears significantly overvalued
- Key risk: Receipt of legal notice invoking arbitration in a disputed matter
What is the future outlook for Titan Biotech Ltd?
Titan Biotech Ltd's forward outlook based on current data signals
- Earnings Trend: turning around (inflection up)
- Revenue Trend: turning around (inflection up)
- Margin Trend: volatile
- Valuation: Significantly Overvalued
- Key Catalyst: Demerger Spin Off Value Unlock
- Key Risk: Receipt of legal notice invoking arbitration in a disputed matter
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.